Here are some common abbreviations. They are taken from the 2022 ERS/ESC PH guidelines.
| 6MWD | 6-minute walking distance |
| 6MWT | 6-minute walking test |
| ABG | Arterial blood gas analysis |
| ACEi | Angiotensin-converting enzyme inhibitor |
| ALAT | Alanine aminotransferase |
| ARB | Angiotensin receptor blocker |
| ARNI | Angiotensin receptor–neprilysin inhibitor |
| ASAT | Aspartate aminotransferase |
| ASIG | Australian Scleroderma Interest Group |
| BNP | Brain natriuretic peptide |
| BPA | Balloon pulmonary angioplasty |
| BPD | Bronchopulmonary dysplasia |
| CAMPHOR | Cambridge Pulmonary Hypertension Outcome Review |
| CCB | Calcium channel blocker |
| CDH | Congenital diaphragmatic hernia |
| cGMP | Cyclic guanosine monophosphate |
| CHD | Congenital heart disease |
| CI | Cardiac index; Confidence interval |
| cMRI | Cardiac magnetic resonance imaging |
| CO | Cardiac output |
| COMPERA | Comparative, Prospective Registry of Newly Initiated Therapies for PH |
| COPD | Chronic obstructive pulmonary disease |
| CpcPH | Combined post- and pre-capillary pulmonary hypertension |
| CPET | Cardiopulmonary exercise testing |
| CPFE | Combined pulmonary fibrosis and emphysema |
| CT | Computed tomography |
| CTD | Connective tissue disease |
| CTEPD | Chronic thrombo-embolic pulmonary disease |
| CTEPH | Chronic thrombo-embolic pulmonary hypertension |
| CTPA | Computed tomography pulmonary angiography |
| DECT | Dual-energy computed tomography |
| DLCO | Lung diffusion capacity for carbon monoxide |
| DPAH | Drug- or toxin-associated pulmonary arterial hypertension |
| dPAP | Diastolic pulmonary arterial pressure |
| DPG | Diastolic pressure gradient |
| DSA | Digital subtraction angiography |
| ECG | Electrocardiogram |
| ECMO | Extracorporeal membrane oxygenation |
| EHJ | European Heart Journal |
| EMA | European Medicines Agency |
| EOV | Exercise oscillatory ventilation |
| ERA | Endothelin receptor antagonist |
| ERJ | European Respiratory Journal |
| ERN | European Reference Network |
| ERN-LUNG | European Reference Network on rare respiratory diseases |
| ERS | European Respiratory Society |
| ESC | European Society of Cardiology |
| EtD | Evidence to Decision |
| FPHR | French Pulmonary Hypertension Registry |
| FVC | Forced vital capacity |
| GRADE | Grading of Recommendations, Assessment, Development, and Evaluations |
| HAART | Highly active antiretroviral therapy |
| Hb | Haemoglobin |
| HF | Heart failure |
| HFpEF | Heart failure with preserved ejection fraction |
| HIV | Human immunodeficiency virus |
| HPAH | Heritable pulmonary arterial hypertension |
| HPS | Hepatopulmonary syndrome |
| HR | Hazard ratio |
| HR-QoL | Health-related quality of life |
| ICU | Intensive care unit |
| IgG4 | Immunogolobulin G4 |
| ILD | Interstitial lung disease |
| IPAH | Idiopathic pulmonary arterial hypertension |
| IpcPH | Isolated post-capillary pulmonary hypertension |
| IP receptor | Prostacyclin I2 receptor |
| ISWT | Incremental shuttle walking test |
| i.v. | Intravenous |
| LA | Left atrium/left atrial |
| LAS | Lung allocation score |
| LHD | Left heart disease |
| LTx | Lung transplantation |
| LV | Left ventricle/left ventricular |
| LVAD | Left ventricular assist device |
| mPAP | Mean pulmonary arterial pressure |
| MR | Magnetic resonance |
| MRI | Magnetic resonance imaging |
| NOAC | Novel oral anticoagulant |
| NT-proBNP | N-terminal pro-brain natriuretic peptide |
| OR | Odds ratio |
| PA | Pulmonary artery |
| PAC | Pulmonary arterial compliance |
| PaCO2 | Partial pressure of arterial carbon dioxide |
| PADN | Pulmonary artery denervation |
| PAH | Pulmonary arterial hypertension |
| PAH-CTD | Pulmonary arterial hypertension associated with connective tissue disease |
| PAH-SSc | Pulmonary arterial hypertension associated with systemic sclerosis |
| PAH-SYMPACT | Pulmonary Arterial Hypertension-Symptoms and Impact |
| PaO2 | Partial pressure of arterial oxygen |
| PAP | Pulmonary arterial pressure |
| PAVM | Pulmonary arteriovenous malformation |
| PAWP | Pulmonary arterial wedge pressure |
| PCH | Pulmonary capillary haemangiomatosis |
| PDE5i | Phosphodiesterase 5 inhibitor |
| PE | Pulmonary embolism |
| PEA | Pulmonary endarterectomy |
| PET | Positron emission tomography |
| PETCO2 | End-tidal partial pressure of carbon dioxide |
| PFT | Pulmonary function test |
| PH | Pulmonary hypertension |
| PH-LHD | Pulmonary hypertension associated with left heart disease |
| PICO | Population, Intervention, Comparator, Outcome |
| PoPH | Porto-pulmonary hypertension |
| PPHN | Persistent pulmonary hypertension of the newborn |
| PROM | Patient-reported outcome measure |
| PVD | Pulmonary vascular disease |
| PVOD | Pulmonary veno-occlusive disease |
| PVR | Pulmonary vascular resistance |
| PVRI | Pulmonary vascular resistance index |
| QI | Quality indicator |
| Qp/Qs | Pulmonary blood flow/systemic blood flow |
| RA | Right atrium/right atrial |
| RAP | Right atrial pressure |
| RCT | Randomized controlled trial |
| REVEAL | Registry to Evaluate Early and Long-Term PAH Disease Management |
| RHC | Right heart catheterization |
| RR | Relative risk |
| RV | Right ventricle/right ventricular |
| RVEF | Right ventricular ejection fraction |
| RV-FAC | Right ventricular fractional area change |
| RVOT AT | Right ventricular outflow tract acceleration time |
| SaO2 | Arterial oxygen saturation |
| s.c. | Subcutaneous |
| SCD | Sickle cell disease |
| sGC | Soluble guanylate cyclase |
| SGLT-2i | Sodium–glucose cotransporter-2 inhibitor |
| SLE | Systemic lupus erythematosus |
| SPAHR | Swedish Pulmonary Arterial Hypertension Registry |
| sPAP | Systolic pulmonary arterial pressure |
| SPECT | Single-photon emission computed tomography |
| SSc | Systemic sclerosis |
| SV | Stroke volume |
| SVI | Stroke volume index |
| SvO2 | Mixed venous oxygen saturation |
| TAPSE | Tricuspid annular plane systolic excursion |
| TGF-β | Transforming growth factor-β |
| TPR | Total pulmonary resistance |
| TR | Tricuspid regurgitation |
| TRPG | Tricuspid regurgitation pressure gradient |
| TRV | Tricuspid regurgitation velocity |
| TSH | Thyroid-stimulating hormone |
| V/Q | Ventilation perfusion |
| VE/VCO2 | Ventilatory equivalent for carbon dioxide |
| VKA | Vitamin K antagonist |
| VO2 | Oxygen uptake |
| VO2/HR | Oxygen pulse |
| VTE | Venous thrombo-embolism |
| WHO-FC | World Health Organization functional class |
| WSPH | World Symposium on Pulmonary Hypertension |
| WU | Wood units |
Copied from the Guidelines for Pulmonary Hypertension 2022